Cargando…

PW02-041 - Canakinumab treatment regimens in CAPS-patients

Detalles Bibliográficos
Autores principales:	Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952126/ http://dx.doi.org/10.1186/1546-0096-11-S1-A182

Ejemplares similares

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

PW02-040 - Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

PW02-037 - The Eurofever cohort of 136 patients with CAPS
por: Levy, R, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

PReS-FINAL-2331: Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

PW02-031 - Genetic and clinical manifestations of CAPS
por: Bybee, AK, et al.
Publicado: (2013)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

PW02-007 - The Eurofever registry: 3 years of enrollment
por: Federici, S, et al.
Publicado: (2013)

PW02-027 - CAPS and cost-effectiveness analysis project
por: Alberighi, O Della Casa, et al.
Publicado: (2013)

PW02-033 - Cytokine profile in CSF in CAPS patients
por: Schuh, E, et al.
Publicado: (2013)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

PW02-025 - Programme necrosis by CAPS-associated NLRP3
por: Satoh, T, et al.
Publicado: (2013)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

PW02-034 - NLRP3 mosaicism detection in CAPS using NGS
por: Stoffels, M, et al.
Publicado: (2013)

PW02-026 - Low frequency variants of NLRP3 in CAPS patients
por: Lesche, M, et al.
Publicado: (2013)

PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013)

PW02-042 - Induction of MDSC in Muckle-Wells syndrome
por: Rieber, N, et al.
Publicado: (2013)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

PW02-028 - Association of novel NLRP3 mutations with CAPS phenotype in Turkish patients
por: Berdeli, A, et al.
Publicado: (2013)

P02-028 - Muckle-Wells syndrome and renal transplantation
por: Kortus-Götze, B, et al.
Publicado: (2013)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
por: Gautier, A, et al.
Publicado: (2013)

P02-008 - Dramatic response to canakinumab in MKD
por: Makay, B, et al.
Publicado: (2013)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

PW02-001 - Exome sequencing for autoinflammatory disorders
por: Boyden, SE, et al.
Publicado: (2013)

PW02-023 - Qualitative aspects of autoinflammatory diseases
por: Konukbay, D, et al.
Publicado: (2013)

PW02-038 - Treatment-resistant NOMID with autoantibodies
por: Broderick, L, et al.
Publicado: (2013)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Unmet psychosocial needs in CAPS
por: Erbis, G, et al.
Publicado: (2015)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

PW01-008 – The inflammasome and secretory pathways in FMF
por: Orak, B, et al.
Publicado: (2013)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

PW02-003 - Efficacy of anakinra in etanercept-resistant TRAPS
por: Ombrello, AK, et al.
Publicado: (2013)

PW02-017 - New tools for the ISSAID society website
por: Touitou, I, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cpv0h066v4du7dbj4mgkid4s9e